[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 37 pages | ID: NFB0F0F09B80EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Drugs In Development, 2022, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 1 and 2 respectively.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type II - Overview
Neurofibromatoses Type II - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neurofibromatoses Type II - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type II - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beta Pharma Inc
BioXcel Corp
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
OncoTherapy Science Inc
Plex Pharmaceuticals Inc
PRG S&Tech Inc
Recursion Pharmaceuticals Inc
Neurofibromatoses Type II - Drug Profiles
bortezomib - Drug Profile
Product Description
Mechanism Of Action
History of Events
brigatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MUL-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRG-NF - Drug Profile
Product Description
Mechanism Of Action
REC-2282 - Drug Profile
Product Description
Mechanism Of Action
History of Events
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Neurofibromatoses Type II - Dormant Projects
Neurofibromatoses Type II - Product Development Milestones
Featured News & Press Releases
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Neurofibromatoses Type II, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, 2022
Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, 2022
Neurofibromatoses Type II - Pipeline by BioXcel Corp, 2022
Neurofibromatoses Type II - Pipeline by Millennium Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Pipeline by Mulberry Biotherapeutics Inc, 2022
Neurofibromatoses Type II - Pipeline by OncoTherapy Science Inc, 2022
Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Pipeline by PRG S&Tech Inc, 2022
Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Dormant Projects, 2022

LIST OF FIGURES

Number of Products under Development for Neurofibromatoses Type II, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications